The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans

Daniel R. Carrasco,1,3 Tim Fenton,2 Kumar Sukhdeo,1 Marina Protopopova,1,4 Miriam Enos,1 Mingjian J. You,3 Dolores Di Vizio,1 Cristina Nogueira,1 Jayne Stommel,1 Geraldine S. Pinkus,3 Christopher Fletcher,3 Jason L. Hornick,3 Webster K. Cavenee,2 Frank B. Furnari,2 and Ronald A. DePinho1,4,*

1 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115
2 Ludwig Institute for Cancer Research, University of California, San Diego, School of Medicine, La Jolla, California 92093
3 Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115
4 Center for Applied Cancer Science, Belfer Foundation Institute for Innovative Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
*Correspondence: ron_depinho@dfci.harvard.edu

(Cancer Cell 9, 379–390; May 2006)
In this article, coauthor Dolores Di Vizio was listed incorrectly as Dolores Divicio. The correct author list is printed above.

DOI: 10.1016/j.ccr.2006.07.012